A Race between Tumor Immunoescape and Genome Maintenance Selects for Optimum Levels of (epi)genetic Instability

The human immune system functions to provide continuous body-wide surveillance to detect and eliminate foreign agents such as bacteria and viruses as well as the body's own cells that undergo malignant transformation. To counteract this surveillance, tumor cells evolve mechanisms to evade elimination by the immune system; this tumor immunoescape leads to continuous tumor expansion, albeit potentially with a different composition of the tumor cell population (“immunoediting”). Tumor immunoescape and immunoediting are products of an evolutionary process and are hence driven by mutation and selection. Higher mutation rates allow cells to more rapidly acquire new phenotypes that help evade the immune system, but also harbor the risk of an inability to maintain essential genome structure and functions, thereby leading to an error catastrophe. In this paper, we designed a novel mathematical framework, based upon the quasispecies model, to study the effects of tumor immunoediting and the evolution of (epi)genetic instability on the abundance of tumor and immune system cells. We found that there exists an optimum number of tumor variants and an optimum magnitude of mutation rates that maximize tumor progression despite an active immune response. Our findings provide insights into the dynamics of tumorigenesis during immune system attacks and help guide the choice of treatment strategies that best inhibit diverse tumor cell populations.

[1]  Bert Vogelstein,et al.  Mutations of mitotic checkpoint genes in human cancers , 1998, Nature.

[2]  S. Pettit,et al.  Immune selection in neoplasia: towards a microevolutionary model of cancer development , 2000, British Journal of Cancer.

[3]  D. Wodarz,et al.  Evolutionary dynamics of mutator phenotypes in cancer: implications for chemotherapy. , 2003, Cancer research.

[4]  Adelheid Cerwenka,et al.  Natural killer cells, viruses and cancer , 2001, Nature Reviews Immunology.

[5]  L. Loeb,et al.  A mutator phenotype in cancer. , 2001, Cancer research.

[6]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[7]  Manfred Eigen,et al.  Error catastrophe and antiviral strategy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[8]  A. Hayday,et al.  Regulation of cutaneous malignancy by gammadelta T cells. , 2001, Science.

[9]  M. Smyth,et al.  Innate Immune Surveillance of Spontaneous B Cell Lymphomas by Natural Killer Cells and γδ T Cells , 2004, The Journal of experimental medicine.

[10]  P. Krammer,et al.  Tumor Immunology , 2018, Medical Immunology.

[11]  R. D. de Boer,et al.  Understanding the Failure of CD8+ T-Cell Vaccination against Simian/Human Immunodeficiency Virus , 2007, Journal of Virology.

[12]  Sayuri Yamazaki,et al.  Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance , 2001, Immunological reviews.

[13]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[14]  H. Thomas,et al.  Genetic instability in colorectal cancer , 1998, Gut.

[15]  A. d’Onofrio A general framework for modeling tumor-immune system competition and immunotherapy: Mathematical analysis and biomedical inferences , 2005, 1309.3337.

[16]  Michael Loran Dustin,et al.  Neural and Immunological Synaptic Relations , 2002, Science.

[17]  M. Smyth,et al.  NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. , 2001, International immunology.

[18]  W. Grady,et al.  Genomic and epigenetic instability in colorectal cancer pathogenesis. , 2008, Gastroenterology.

[19]  Rob J. de Boer,et al.  Understanding the failure of CD8 T-cell vaccination against simian/human immunodeficiency virus , 2007 .

[20]  E. Domingo,et al.  Mutagenesis versus Inhibition in the Efficiency of Extinction of Foot-and-Mouth Disease Virus , 2003, Journal of Virology.

[21]  L. Loeb,et al.  Viral error catastrophe by mutagenic nucleosides. , 2004, Annual review of microbiology.

[22]  N. Restifo,et al.  Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.

[23]  P Hogeweg,et al.  Macrophage T lymphocyte interactions in the anti-tumor immune response: a mathematical model. , 1985, Journal of immunology.

[24]  M. Burnet Cancer—A Biological Approach , 1957, British medical journal.

[25]  A. Nowak,et al.  Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. , 2003, Cancer research.

[26]  A. Perelson,et al.  Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. , 1994, Bulletin of mathematical biology.

[27]  J. Trapani,et al.  Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells , 2000, The Journal of experimental medicine.

[28]  C. Janeway Immunobiology: The Immune System in Health and Disease , 1996 .

[29]  Hua Yu,et al.  Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells , 2004, Nature Medicine.

[30]  R. Herberman,et al.  Natural cell-mediated immunity. , 1978, Advances in cancer research.

[31]  Samuel Litwin,et al.  Examining The Theory of Error Catastrophe , 2006, Journal of Virology.

[32]  H. Schreiber,et al.  Immunodominance and tumor escape. , 2002, Seminars in cancer biology.

[33]  M. Nowak,et al.  Decay Kinetics of Human Immunodeficiency Virus-Specific Effector Cytotoxic T Lymphocytes after Combination Antiretroviral Therapy , 1999, Journal of Virology.

[34]  R. Schreiber,et al.  The three Es of cancer immunoediting. , 2004, Annual review of immunology.

[35]  Eric B Haura,et al.  Mechanisms of Disease: insights into the emerging role of signal transducers and activators of transcription in cancer , 2005, Nature Clinical Practice Oncology.

[36]  M BURNET,et al.  Cancer—A Biological Approach* , 1957, British medical journal.

[37]  Julia M. Lewis,et al.  Regulation of Cutaneous Malignancy by γδ T Cells , 2001, Science.

[38]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[39]  Michael Lachmann,et al.  Quasispecies Made Simple , 2005, PLoS Comput. Biol..

[40]  E. Shakhnovich,et al.  Genetic instability and the quasispecies model. , 2006, Journal of theoretical biology.

[41]  H. Ljunggren,et al.  Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL-10. , 1997, Journal of immunology.

[42]  I. Svane,et al.  Methylcholanthrene‐induced sarcomas in nude mice have short induction times and relatively low levels of surface MHC class I expression , 1996, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[43]  C. Cameron,et al.  RNA virus error catastrophe: Direct molecular test by using ribavirin , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[44]  K. Kinzler,et al.  Genetic instabilities in human cancers , 1998, Nature.

[45]  Federico Garrido,et al.  MHC class I antigens, immune surveillance, and tumor immune escape , 2003, Journal of cellular physiology.

[46]  H. P. de Vladar,et al.  Dynamic response of cancer under the influence of immunological activity and therapy. , 2004, Journal of theoretical biology.

[47]  B. Robinson,et al.  Immunotherapy and chemotherapy — a practical partnership , 2005, Nature Reviews Cancer.

[48]  K. Kinzler,et al.  Genetic instability in colorectal cancers , 1997, Nature.

[49]  R. Schreiber,et al.  A critical function for type I interferons in cancer immunoediting , 2005, Nature Immunology.

[50]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[51]  Ricard V Solé,et al.  An error catastrophe in cancer? , 2004, Journal of theoretical biology.

[52]  Lisette G de Pillis,et al.  A validated mathematical model of cell-mediated immune response to tumor growth. , 2007, Cancer research.

[53]  M. Zali,et al.  Genomic and Epigenetic Instability in Colorectal Cancer , 2013 .

[54]  D. Davis,et al.  Intrigue at the immune synapse. , 2006, Scientific American.

[55]  S. Rosenberg,et al.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy , 2008, Nature Reviews Cancer.

[56]  Gavin P Dunn,et al.  Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. , 2006, Advances in immunology.